University of South Florida

Scholar Commons
Internal Medicine Faculty Publications

Internal Medicine

8-1-2012

Dha Derivatives of Fish Oil as Dietary Supplements: a NutritionBased Drug Discovery Approach for Therapies to Prevent
Metabolic Cardiotoxicity
Yonggang Ma
University of Texas at San Antonio

Merry L. Lindsey
University of Texas at San Antonio

Ganesh V. Halade
University of Texas at San Antonio, ghalade@usf.edu

Follow this and additional works at: https://scholarcommons.usf.edu/intmed_facpub

Scholar Commons Citation
Ma, Yonggang; Lindsey, Merry L.; and Halade, Ganesh V., "Dha Derivatives of Fish Oil as Dietary
Supplements: a Nutrition-Based Drug Discovery Approach for Therapies to Prevent Metabolic
Cardiotoxicity" (2012). Internal Medicine Faculty Publications. 64.
https://scholarcommons.usf.edu/intmed_facpub/64

This Review is brought to you for free and open access by the Internal Medicine at Scholar Commons. It has been
accepted for inclusion in Internal Medicine Faculty Publications by an authorized administrator of Scholar
Commons. For more information, please contact scholarcommons@usf.edu.

NIH Public Access
Author Manuscript
Expert Opin Drug Discov. Author manuscript; available in PMC 2014 March 29.

NIH-PA Author Manuscript

Published in final edited form as:
Expert Opin Drug Discov. 2012 August ; 7(8): 711–721. doi:10.1517/17460441.2012.694862.

DHA derivatives of fish oil as dietary supplements: a nutritionbased drug discovery approach for therapies to prevent
metabolic cardiotoxicity
Yonggang Ma, PhD, Merry L. Lindsey, PhD, and Ganesh V. Halade, PhD†
The University of Texas Health Science Center at San Antonio, Division of Geriatrics,
Gerontology and Palliative Medicine, Department of Medicine, San Antonio, TX, USA

Abstract

NIH-PA Author Manuscript

Introduction—During the early 1970s, Danish physicians Jorn Dyerberg and colleagues
observed that Greenland Eskimos consuming fatty fishes exhibited low incidences of heart
disease. Fish oil is now one of the most commonly consumed dietary supplements. In 2004,
concentrated fish oil was approved as a drug by the FDA for the treatment of hyperlipidemia. Fish
oil contains two major omega-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA). With advancements in lipid concentration and purification techniques, EPA- or
DHA-enriched products are now commercially available, and the availability of these components
in isolation allows their individual effects to be examined. Newly synthesized derivatives and
endogenously discovered metabolites of DHA exhibit therapeutic utility for obesity, metabolic
syndrome and cardiovascular disease.
Areas covered—This review summarizes our current knowledge on the distinct effects of EPA
and DHA to prevent metabolic syndrome and reduce cardiotoxicity risk. Since EPA is an integral
component of fish oil, we will briefly review EPA effects, but our main theme will be to
summarize effects of the DHA derivatives that are available today. We focus on using nutritionbased drug discovery to explore the potential of DHA derivatives for the treatment of obesity,
metabolic syndrome and cardiovascular diseases.

NIH-PA Author Manuscript

Expert opinion—The safety and efficacy evaluation of DHA derivatives will provide novel
biomolecules for the drug discovery arsenal. Novel nutritional-based drug discoveries of DHA
derivatives or metabolites may provide realistic and alternative strategies for the treatment of
metabolic and cardiovascular disease.
Keywords
cardiovascular disease; dietary supplement; docosahexaenoic acid; eicosapentaenoic acid; fish oil;
metabolic syndrome; obesity
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1. Introduction
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In the 1970s, Danish physicians described the plasma lipid and lipoprotein patterns of
Eskimos living on the west coast of Greenland and compared their diet with that only typical
for the Danish population [1]. Two of these physicians, Dyerberg and Bang, further
determined that blood obtained from Eskimos had a nearly twofold longer clotting time than
blood from Danes, and that this difference in clotting time positively correlated to the low
mortality from coronary heart disease among the Eskimos, compared with rates for the
Danes. Moreover, platelets isolated from Eskimos showed reduced aggregability following
exposure to adenosine diphosphate and collagen, compared with platelets isolated from
Danes [2]. Since the percentages of dietary fat intake was similar between Greenland
Eskimos and Danes, but lipid profiling indicated reduced concentration of linoleic acid in
Eskimos, a theory developed that the striking difference in coronary heart disease could be
due to the large difference in the intake of marine fats in Eskimos [3]. This was the
beginning of the past 40 years of research on fish oil effects on human health.
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Omega-3 fatty acids are n-3 long chain polyunsaturated fatty acids (LC-PUFA). The two
major n-3 LC-PUFAs are eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid
(DHA; 22:6n-3), and both are found in marine fish oils and have been found to be effective
for the treatment of hyperlipidemia in mice and rats [4,5] as well as in humans [6,7]. While
the majority of studies have focused on cardiovascular effects, fish oil has also been shown
to be effective for the treatment of lupus, kidney disease [8], osteoporosis [9] and macular
degeneration [10].
The Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico (GISSI)
Prevenzione trial established that omega-3 dietary supplementation (1 g/d) reduced the risk
of cardiovascular death by 45% in a patient population of > 2000 patients, all of whom had
experienced a previous myocardial infarction [11]. Of note, a diet rich in omega-3 fatty
acids is currently recommended by the American Heart Association (http://
www.americanheart.org, accessed on 16 Jan 2012). A wide range of research has shown that
fish oil reduces the risk of major cardiovascular events, including myocardial infarction,
sudden cardiac death, coronary heart disease, atrial fibrillation and death in patients with
heart failure [12–15]. By contrast, a recent meta-analysis performed by Kwak et al.
concluded that there was insufficient evidence to indicate a secondary preventive effect of
omega-3 fatty acid supplements against overall cardiovascular events among patients with a
history of cardiovascular disease [16]. Fish oil has anti-inflammatory and anti-arrhythmic
effects, as well as improves endothelial cell and platelet functions [17,18].
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The National Health and Nutrition Examination Survey (NHNES) first pointed out an
alarming prevalence of obesity in the 1990s, and this prevalence has continued to be high for
the last decade (1999 – 2010) [19]. Obesity is defined as a body mass index of 30 or greater
(calculated as weight in kilograms divided by height in meters squared). One in every three
adults and one in every six children in the US is obese [19], and obesity is the most robust
risk factor for the development of type 2 diabetes [20]. Gonzalez-Periz established that
omega-3 fatty acids protect against obesity-induced inflammation. Omega-3 fatty acids
increase synthesis of the bioactive lipid mediators protectin D1 and resolvin D1 and
decrease the synthesis of the omega-6-derived eicosanoids cyclooxygenase, prostaglandins
and lipoxygenase in adipose tissue, despite having no effect on body weight. Additionally,
omega-3 fed mice show increased adipose tissue mRNA expression of genes known to be
protective against systemic insulin resistance, including adiponectin, peroxisome
proliferator-activated receptor γ and insulin-receptor substrate-1 [21].
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While a large amount of research has been performed to understand the role of fish oil on
many biological processes, focused research is needed to dissect the relative and differential
cardioprotective effects of consuming EPA or DHA, as well as their derivatives and
metabolites. A major concern with fish oil research has been the lack of consistency in
results. This variability is due in large part to differences among studies in dosage, duration,
population target, sample size, assay methods and selection of control or placebo, as well as
differences in the relative concentration of EPA and DHA used in the different supplements
tested. Most studies do not determine the concentration of EPA and DHA in plasma or
serum samples, which makes it difficult to normalize studies based on bioavailability.
Comparative studies focused on the independent effects of EPA and DHA on various
cardiovascular outcomes, particularly in metabolic syndrome, are needed.
In this review article, we will discuss the comparative effects of EPA and DHA present in
fish oil and future directives with particular emphasis on DHA derivatives. We will also
summarize the current literature on fish oil effects on cardiovascular disease, focusing on the
key experiments that explain fish oil mechanisms of action.

2. Distinct effects of EPA and DHA
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Fish oil contains the two chemical species EPA and DHA, which are similar in terms of
functional groups but different in terms of carbon backbone length and degree of
unsaturation. EPA has 20 carbon atoms and 5 double bonds (20:5) while DHA has a longer
chain of 22 carbon atoms and 6 double bonds (22:6). The higher degree of unsaturation in
DHA probably yields increased proton selectivity and conductance by increasing the
permeability of diphytanoylphosphatidylcholine black lipid membranes [18]. These
differences in structure produce much different effects on inflammation, blood pressure and
heart rate, endothelial function, atherosclerosis and post-myocardial infarction effects on
collagen deposition.
2.1 Inflammation
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Obesity-mediated low-grade chronic systemic inflammation contributes to the development
of type 2 diabetes and cardiovascular disease [22]. The factor that has contributed to the
overweight and obese populations in the US has been the increased consumption of linoelic
and essential fatty acids [23]. Linoleic acid-enriched soybean oil consumption has increased
from 0.006 to 7.38% during the twentieth century. During this same period, linoleic acid
content in breast milk has increased from 6 – 7% to 15 – 16% of total fatty acid
composition. Adipose tissue linoleic acid content has increased from 6% in 1960 to 18% in
1986 [24]. While clinical studies have not been able to directly link obesity to an increased
intake of only linoleic acid due to the complex composition of the diets used in those
studies, studies in rodents clearly indicate that chronic consumption of a linoleic acidenriched n-6 fatty acid diet leads to obesity [25–27].
Replacement of n-6 fatty acids with n-3 LCPUFA prevents the progression of obesity in
high-fat-fed rats [28]. Alvheim et al. showed that increased consumption of linoleic acid in
C57BL/6J mice enhanced arachidonic acid levels, which stimulated endocannabinoids 2arachidonoylglycerol and anandamide synthesis. These products stimulate cannabinoid
receptors to modulate central and peripheral responses, which stimulate appetite, increase
food intake, activate fat storage pathways, promote adipocyte inflammation and
downregulate catabolism. All of these combined functions result in adipose accumulation.
Simultaneous dietary supplementation of EPA and DHA decreases the obesogenic effects of
linoleic acid [27,29]. Oh et al. showed that the G protein-coupled receptor (GPR) 120 is a
functional receptor that mediates potent insulin-sensitizing and anti-diabetic effects to
reduce macrophage-induced tissue inflammation in mice [30]. A high-fat diet stimulated
Expert Opin Drug Discov. Author manuscript; available in PMC 2014 March 29.
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production of the M1 inflammatory genes interleukin (IL)-6, tumor necrosis factor (TNF)-α,
monocyte chemotactic protein-1, IL-1β, inducible nitric oxide synthase and CD11c in both
wild-type (WT) and GPR null adipose tissue. Interestingly, n-3 fatty acid supplementation
reduced inflammatory genes only in WT not GPR null mice. Similarly, the M2 antiinflammatory genes, arginase 1, IL-10, macrophage galactose N-acetyl-galactosaminespecific lectin 1, Ym-1, Clec7a and macrophage mannose receptor were all increased by n-3
fatty acids in WT, but not in GPR120 null, adipose tissue. As GPR120 is highly expressed in
pro-inflammatory M1 (but not M2) macrophages, this receptor probably serves as an n-3
fatty acid receptor to inhibit both the toll-like receptor (TLR)-2/3/4 and the TNF-αstimulated responses to induce insulin sensitization [30].
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The pro-inflammatory markers IL-6, C-reactive protein (CRP) and TNF-α are inversely
correlated with levels of n-3 fatty acids in plasma as well as in erythrocytes, suggesting that
the cardioprotective effects of fish oil supplementation may be through inhibiting these
mediators [31–36]. Bouwens et al. demonstrated that fish oil decreased the expression of
NF-κB target genes, pro-inflammatory cytokines and eicosanoid synthesis genes in
peripheral blood mononuclear cells [37]. DHA, but not EPA, reduced serum anti-doublestranded DNA antibodies and IgG deposition in kidneys. DHA also lowered
lipopolysaccharide-mediated increases in serum IL-18 levels, as well as reduced caspase-1dependent cleavage of pro-IL-18 to mature IL-18 in the kidneys [38]. In addition, DHA
dramatically extended both the median and the maximal life span of (NZBXNZW)F1 mixed
background mice, while EPA had only a marginal effect on median and maximal life span of
lupus-prone mice [38]. Mori et al. showed that urinary F2-isoprostanes were reduced 19%
by EPA and 20% by DHA, with no changes in CRP, IL-6 or TNF-α levels [39]. The exact
mechanism of how anti-inflammatory properties of DHA could translate to increased life
span, therefore, requires additional investigation.
2.2 Blood pressure and heart rate
The third NHANES indicates that uncontrolled and untreated hypertension strongly
associated with increased risk of total and cardiovascular mortality [40]. Law et al.
demonstrated that reducing blood pressure decreased the overall mortality risk by 22% and
reduced the risk of stroke by 41% [41]. Numerous epidemiological and interventional
studies in patients with previous myocardial infarction have demonstrated a hypotensive role
of fish oils [42]. Morris and co-workers showed that fish oil not only reduced blood pressure
but also benefited patients with atherosclerosis or hypercholesterolemia [43].
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Only a few human studies, however, have segregated the distinct effect of EPA and DHA on
blood pressure [44–46]. Mori and his colleagues first established the differential effects of
purified EPA and DHA on forearm vascular reactivity in overweight hyperlipidemic men.
They showed that DHA, but not EPA, enhanced vasodilation and attenuated constrictor
responses in the forearm microcirculation [47]. DHA (4 g/d) given for 6 weeks reduced 24 h
systolic and diastolic blood pressures in hyperlipidemic male patients, while EPA had no
effect (Figure 1) [39,47,48]. Woodman et al. showed that 4 g/d of EPA or DHA both
improved lipid levels, but both also showed adverse effects on short-term glycemic control,
in hypertensive diabetic patients [44]. Heart rates were not affected in either group. Low
doses of DHA from algal sources (0.7 g/d) have also been shown to decrease diastolic blood
pressure in healthy subjects, indicating that DHA from vegan sources is as effective as DHA
from fish oil [49]. These studies indicate that DHA is more favorable in lowering blood
pressure as well as improving vascular function.
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2.3 Improved endothelial function
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The endothelium regulates vascular structure and tone, and exerts anticoagulant, antiplatelet
and fibrinolytic properties [50]. Vascular endothelium dysfunction stimulates the
development of atherosclerosis. Endothelial dysfunction stimulates leukocyte adhesion and
extravasation [51]. Vascular tone is maintained by numerous dilator and constrictor
substances. Nitric oxide is a major vasodilator substance released by the endothelium, while
endothelin and angiotensin II are the major vasoconstrictor substances [50,51].
The pro-inflammatory cytokines IL-1, IL-4, tumor necrosis factor-α or bacterial endotoxin
decreased vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1
(ICAM-1) and E-selectin expression in cultured human endothelial cells, and DHA (10
μmol/l) suppressed this effect [52]. Omura et al. demonstrated that EPA (30 and 60 μM)
improved NO production by activating eNOS through the Ca2+/calmodulin system in bovine
endothelial cells. EPA stimulated the translocation of endothelial nitric oxide synthase into
the cytosol and its dissociation from caveolin, which prevented its inhibition [53]. By
contrast, neither the EPA metabolite docosapentaenoic acid nor DHA stimulated nitric oxide
production in endothelial cells [53].
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Endothelial function improved following EPA or DHA feeding in both animal models
[54,55] and humans [56]. Long-term supplementation of fish oil (2 weeks to 8 months)
improved endothelium-dependent vasodilation, prevented vasoconstriction or increased
exercise-induced blood flow [33,57–60]. Engler et al. showed that DHA (1.2 g/d for 6
weeks) improved endothelium-dependent flow-mediated dilation in hyperlipidemic children
[61]. The comparative vasodilatory effects of high doses of EPA and DHA (4 g/d for 6
weeks) in overweight mildly hyperlipidemic males (n = 56) showed that DHA, but not EPA,
decreased the vasoconstrictive responses to norepinephrine and increased the vasodilatory
responses to acetylcholine [47]. By contrast, Okumura et al. showed that EPA
supplementation (1.8 g/d for 3 months) improved endothelium-dependent forearm blood
flow response in untreated hypertriglyceridemic male subjects [62]. Dietary supplementation
of DHA (3 g/d, for 90 d) in hypertriglyceridemic men did not alter the circulating levels of
soluble ICAM-1, soluble VCAM-1 and E-selectin [63]. Importantly, the majority markers of
inflammation such as CRP, IL-6 and granulocyte monocyte-colony stimulating factor are
reduced in hypertrigly-ceridemic men [63]. Currently, only a limited number of studies have
been performed, which prevents us from being able to draw conclusions regarding the
differing effects of EPA and DHA on endothelium-dependent vasodilation.
2.4 Atherosclerosis
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Atherosclerosis is the thickening of the arterial wall as a result of the accumulation of the
lipid components cholesterol and triglycerides. The formation of plaques causes artery
narrowing, as well as decreasing vessel flexibility and increasing blood flow resistance. The
formation of plaques in arteries of the heart, lungs or brain can lead to myocardial infarction,
pulmonary embolism or stroke [64]. In the pathological environment of atherosclerosis,
endothelial cells and macrophages in the arterial wall release inflammatory substances,
cytokines and growth factors [65,66].
Fish oil modulates plasma concentrations of lipids, inflammatory markers, adhesion
molecules and lipid peroxidation products that reduce plaque formation, platelet aggregation
and thrombosis. Fish oil intake reduces the risk of atherosclerosis [67–69]. Recent literature
has focused on the prominent use of DHA to prevent coronary artery disease [70,71], Both
EPA and DHA lower triglycerides. DHA, but not EPA, increases both HDL-C and LDL-C
(Table 1) [46,72,73]. Satoh et al. demonstrated that EPA-enriched capsules (of highly
purified > 98% EPA ethyl ester) significantly reduced serum small-density LDL and CRP in
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patients with metabolic syndrome [74]. Amarin Inc., has developed a high EPA-containing
product, is in the FDA drug approval process. This EPA-enriched product reduced LDL-C
levels and also reduced major coronary events by 18% (compared with a 1.7% reduction in
the control group) [75,76].
2.5 Reduced collagen deposition
In the myocardium, cardiac fibroblasts are the main source of extracellular matrix proteins,
including collagen. Following stress or injury, profibrotic cytokines secreted primarily by
leukocytes stimulate fibroblast proliferation and transformation into myofibroblasts.
Myofibroblasts contribute to excessive collagen deposition, which increases ventricular wall
stiffness and compromises filling. This impaired diastolic dysfunction can ultimately result
in congestive heart failure [77,78]. Transforming growth factor (TGF)-β1, a crucial
profibrotic cytokine, promotes cardiac fibroblast phenotype differentiation and collagen
accumulation and also inhibits collagen degradation [79,80]. The cyclic GMP(cGMP)proteinase kinase G (PKG) inhibits TGF-β1-dependent nuclear translocation of phosphoSmad3 by PKG-mediated phosphorylation of the MH2 domain sites of Smad3 to block
profibrotic response [81].
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In a transverse aortic constriction model, 4 weeks of pressure overload induced left
ventricular dysfunction, cardiac fibroblast activation and myocardial fibrosis [82]. Dietary
supplementation with fish oil prevented cardiac dysfunction and blocked fibroblast
activation and collagen production. In vitro, both EPA and DHA inhibited fibroblast
transformation, proliferation and collagen synthesis by suppressing phospho-Smad2/3
nuclear translocation, without affecting Smad2/3 phosphorylation levels. EPA and DHA
exert counter-fibrotic effects, in part by activating the cGMP/PKG signaling pathway.
Dietary supplementation with PUFAs inhibited perivascular fibrosis in a model of high
human renin hypertension and inhibited cardiac fibrosis in diabetic spontaneously
hypertensive rats [83,84]. Microarray and quantitative RT-PCR analysis showed that n-3
PUFAs down-regulated the expression of fibrotic and hypertrophic genes to prevent atrial
fibrillation in a dog model of atrial cardiomyopathy [85]. Kitamura et al. also demonstrated
that EPA attenuated atrial fibrosis and prevented atrial fibrillation-associated heart failure
[86]. Most of the studies shown above examined the effect of fish oil, the combination of
both EPA and DHA, on cardiac fibrosis. However, studies that compare the impact of EPA
versus DHA on myocardial fibrosis are needed.

3. EPA- and DHA-derived lipid mediators for post-MI inflammation
resolution
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The molecular basis for anti-inflammatory action of n-3 PUFAs, using an unbiased LC-MS/
MS-based technology and informatics approach, was devised to identify novel mediators
generated from n-3 PUFAs precursors in response to acute injury. Using this approach, EPA
and DHA were both found to be enzymatically converted into novel potent lipid mediators
termed resolution phase interaction products (resolvins) [87,88]. Resolvins are a new distinct
family of lipid mediators generated from n-3 PUFAs during injury resolution. Importantly,
biosynthesis of resolvins gives rise to stereospecific local mediators that have potent actions
and activate specific receptors.
In the presence of aspirin, both EPA and DHA undergo a series of metabolic transformations
that involve cyclooxygenase and 5-lipoxygenase. E-series resolvins are produced from EPA
and D-series resolvins and neuroprotectin D1 are produced from DHA. A major function of
these metabolites is the resolution of inflammation. EPA- and DHA-derived metabolites
exhibit similarities in anti-inflammatory actions, but are responsible for different mechanism

Expert Opin Drug Discov. Author manuscript; available in PMC 2014 March 29.

Ma et al.

Page 7

NIH-PA Author Manuscript

of action and therapeutic effects in various processes in cardiovascular health and disease.
For example, both resolvin E1 and resolvin D1 decrease the expression of IL-8, TNF-α,
VCAM-1 and monocyte chemotactic protein-1 by endothelial cells and reduce leukocyte
endothelial transmigration [89]. Interestingly, only the DHA-derived compound resolvin D1
decreased prostacyclin production in endothelial cells [89].

4. Potential DHA derivatives for metabolic and cardiovascular disease
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Rossmeisl et al. designed a classical study to evaluate the ability of DHA derivatives to
prevent or reverse obesity and glucose intolerance in high-fat-fed mice [90]. In this study,
four different DHA derivatives (α-methyl DHA ethyl ester; α-ethyl DHA ethyl ester; α,α-dimethyl DHA ethyl ester; and α-thioethyl DHA ethyl ester) were screened for their effects on
body weight and adiposity (Table 2). Out of these four different DHA derivatives, α-ethyl
DHA ethyl ester-fed mice reduced food intake and the feeding efficiency by about 70%.
Moreover, the weight of subcutaneous and epididymal white adipose tissue is decreased by
73 and 42%, respectively. The α-ethyl DHA ethyl ester is a promising DHA derivative in
the treatment of obesity and associated metabolic disturbances. Interestingly, the reduced
adipocyte hypertrophy observed in α-ethyl DHA ethyl ester-fed mice was accompanied by
reduced macrophage infiltration. Important systemic markers of lipid metabolism, such as
triglycerides, non-esterified fatty acids and cholesterol, are also decreased by feeding αethyl DHA ethyl ester in mice [90]. Based on these findings, α-ethyl DHA ethyl ester is a
viable candidate for a nutrition-based drug discovery program for the development of
naturally occurring n-3 fatty acid derivatives. DHA derivatives could qualify as a novel drug
for the treatment of obesity, dyslipidemia, insulin resistance and cardiotoxicity. Tian et al.
discovered the formation of DHA-derived 14S,21R-dihydroxydocosa-4Z,7Z,10Z,12E, 16Z,
19Z-hexaenoic acid (14S,21R-diHDHA) in db/db diabetic mice. Furthermore, exogenous
treatment of 14S,21R-diHDHA in cutaneous wounds counteracted the diabetic impairment
on healing, angiogenesis and associated functions of mesenchymal stem cells in cutaneous
excisional wound healing [91]. Morin et al. determined the effects of the DHA
monoglyceride derivative CRBM-0244 on overreactivity and inflammation in TNF-αtreated human bronchi. CRBM-0244 is synthesized from highly purified DHA attached to a
monoglycerol in the sn-1 position using ethyl docosahexaenoate as the starting material.
This DHA mono-glyceride derivative has potent anti-inflammatory effects and prevented the
degradation of Iκ-Bα and subsequent nuclear translocation of the p65 NF-κB subunit
triggered by TNF-α stimulation. Furthermore, DHA monoglyceride derivative CRBM-0244
reduced airway inflammation in ovalbumin-sensitized lung tissue in guinea pig [92].
Hichami et al. synthesized and evaluated the mechanism of action of DAG-containing
DHA-1-stearoyl-2-docosahexaenoyl-sn-glycerol in the modulation of the responsiveness of
guinea pig airway smooth muscle and increase airway tension [93]. Yamamoto and Itoh
synthesized more than 25 derivatives of DHA and tested these derivatives in Cos cells
(Table 2). These novel compounds such as 4-OH-DHA, 4-oxo-DHA, 5E-4-hydroxy-DHA
and its keto derivatives need to be investigated in more detail [94,95].

5. Fish oil attenuates anthracycline-induced cardiotoxicity
Doxorubicin, an anti-tumor anthracycline antibiotic, not only is widely used for the
treatment of specific types of leukemia but can also induce cardiotoxicity. A single dose of
doxorubicin (20 mg/kg, i.p.) induces ventricular dysfunction in mice. TLR2−/− and TLR4−/−
mice are protected from doxorubicin-induced cardiomyopathy [96,97]. Recently, DHA has
been shown to control differentiation of acute myeloid leukemia cell line KG1 [98].
Adjuvant therapy, with fish oil, DHA-enriched products or with novel DHA derivatives,
provides valid alternatives to prevent anthracycline-induced cardiotoxicity [99].
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6. Caution on adverse effects of fish oil
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Adverse effects of fish oil can occur but are rarely explained or highlighted. Fish oil can
induce platelet dysfunction, resulting in increased bleeding. While fish oil acts as a blood
thinning agent to prevent coronary artery blockage, excessive blood thinning can be
detrimental. Watson and colleagues evaluated bleeding incidences in coronary artery disease
patients receiving high-dose fish oil (mean dose 3.00 ± 1.25 g, DHA 1.125 g and EPA 1.395
g), aspirin (mean dose 161 ± 115 mg) and clopidogrel (mean dose 75 mg) and compared
with controls treated with aspirin and clopidogrel alone. They concluded that high-dose fish
oil was safe in combination with aspirin and clopidogrel and did not increase the risk of
bleeding compared with aspirin and clopidogrel alone [100].
In the Prostate Cancer Prevention Trial, Brasky and co-workers showed that the patients
with the highest percentage of DHA had 2.5 times the risk of developing aggressive, highgrade prostate cancer compared with men with the lowest DHA levels [101]. In agreement
with this observation, DHA supplementation given to SMAD3−/− null mice not only reduced
the symptoms in an inflammatory-like bowel disease model but also increased the risk for
colon cancer [102].

7. Conclusion
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The efficacy of fish oil to treat hyperlipidemia has been established. There is also
compelling evidence that DHA and EPA show distinct pharmacological and therapeutic
effects [6,17,18,73]. The current major focus is on the development of DHA derivatives for
novel drug development for the treatment of metabolic syndrome and cardiovascular disease
(Figure 2).

8. Expert opinion
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Fish oil as a dietary supplement is consumed from a large array of products and by a wide
variety of population groups ranging from newborns to the ageing community. Fish oil is
most often consumed to prevent cardiovascular disease. The variations in response to fish oil
seen over different studies may be due to the different sources, doses and duration of fish oil
used, the test system evaluated, assay sensitivity, patient population and disease condition.
The purity of the fish oil and the concentration of each fatty acid are important
considerations for adequate study design. This may explain why some studies using fish oil
in combination with vitamin E showed a synergistic antioxidant effect that should be further
explored in the future. Many, if not most, studies using disease models are based on the use
of a combination of EPA and DHA; however, EPA, DHA and their individual metabolites or
derivatives stimulate distinct metabolic pathways that could be exploited in isolation for the
treatment of chronic diseases.
In current drug discovery approaches, cardiovascular safety concerns continue to be a
leading reason for drug failures during development, leading to product withdrawal. There
have been a number of notable product withdrawals, including terfenadine, cisapride,
rofecoxib and rosiglitazone (withdrawn from the European market and prescribed with
warning in US). The failure rate of current drug discovery is substantially high, with one
compound reaching the market for every 1000 compounds that are successful in vitro. A
focused nutritional approach may allow us to reduce the failure rate of drug molecules,
particularly for those compounds that originate from EPA and DHA derivatization or
metabolism. The principal benefit to using a nutrition-based drug discovery program, in
combination with current drug discovery approaches, is that EPA and DHA are
biomolecules, as well as their derivatives, and may provide novel treatments for obesity,
insulin resistance and diabetes. Pharmacokinetics and pharmacodynamics studies of EPAExpert Opin Drug Discov. Author manuscript; available in PMC 2014 March 29.
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and DHA-derived biomolecules will help to drive the field toward the successful
translational application of novel biomolecules. Multidimensional cellular, molecular and
lipidomic tools will need to be integrated with current LIPID MAPS databases in order to
specifically dissect the pharmacological mechanisms in particular disease models. A major
research focus on DHA derivatives to study the inter-relationship between obesity,
metabolic syndrome and cardiovascular disease will enable us to identify and develop novel
drugs for these syndromes.
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Based on the differential effects of EPA and DHA, future perspectives and key experimental
strategies should be focused on the successful development of novel biomolecules using
nutrition-based drug discovery approaches. Although the AHA has recommended a diet rich
in PUFA, future studies examining the effects of n-6 fatty acids versus EPA or DHA may
help the AHA to refine the current statement [103]. Directive areas should be focused to
combat the dramatic increase in n-6 fatty acids in our current diet. The additional
development of n-3 fatty acid (e.g., DHA)-derived biomolecules is needed, to compete with
the deleterious effects of n-6 fatty acid intake. The priority and comprehensive evaluation of
novel EPA and DHA biomolecules based on a nutrition-based drug discovery will provide
therapeutic tools for various diseases. The efficacy and safety of novel EPA and DHA
derivatives will help to clarify dietary guidance on recommendations for EPA and DHA.
Prioritizing the evaluation of EPA- and DHA-derived biomolecules based on structural and
activity relationships will add novel molecules for the drug discovery arsenal to treat obesity
and cardiovascular disease.
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•

Observational evidence suggested that seafood promotes health, which led to the
development of fish oil as a dietary supplement. This eventually culminated in
the FDA approval for concentrated fish oil as a drug for the treatment of
hyperlipidemia.

•

Fish oil is composed of two main constituents: eicosapentaenoic acid and
docosahexaenoic acid, which are chemically different and possess distinct
pharmacological and therapeutic potentials.

•

Newly synthesized derivatives and endogenously discovered metabolites of
DHA exhibit therapeutic utility for obesity, metabolic syndrome and
cardiovascular disease.

•

Novel DHA derivatives and metabolites have high drug candidate potential, but
more detailed investigations are needed for the successful translation of
biomolecules developed from a nutrition-based drug discovery process into
human use.

This box summarizes key points contained in the article.
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Figure 1. Summary of the known roles of eicosapentaenoic acid (EPA) + docosahexaenoic acid
(DHA), compared with the differential roles of EPA and DHA in isolation

EPA-specific effects are denoted in the green circle. DHA-specific effects are denoted in
brown circle. Effects that are seen with the combination of EPA and DHA are denoted in the
blue ellipse.
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Figure 2. A nutrition-based fatty acid drug discovery program was used during the journey from
observing the benefits of a seafood diet to the development of new docosahexaenoic acid (DHA)derived biomolecules for the prevention and treatment of metabolic syndrome, cardiovascular
disease and inflammatory disease
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Table 1

NIH-PA Author Manuscript

Key mechanistic studies that elucidate the distinct effects of eicosapentaenoic acid (EPA) and
docosahexaenoic acid (DHA) [6,39,42,47,63,72,74,104].
Clinical outcome/markers

EPA

DHA

Blood pressure

N.S.

↓ Blood pressure, ↓ Heart rate, ↑ Vascular
function

Platelet volume and numbers

↓ platelet volume and ↑platelet
count

N.S.

Serum metabolites: TG, insulin, HDL cholesterol

↓ TGs, ↑ Insulin

↓ TGs, ↑ Insulin, ↑ HDL and HDL2 cholesterol

High- and low-density cholesterol HDL-C and LDL-C

↓ LDL-C

↑ HDL-C, ↑ LDL-C

Oxidative stress

↓ F2-isoprostanes

↓ F2-isoprostanes

Inflammatory markers

↓ TNF-α

↓CRP, ↓IL-6, ↓G-MCSF, ↓ TNF-α

This table was modified from [6] with permission of the American Society for Nutrition.
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Table 2

NIH-PA Author Manuscript

Docosahexaenoic acid (DHA) derivatives and metabolites that are currently in pipeline for screening for the
treatment of various pharmacological and therapeutic targets [90–92,94,95,105].

NIH-PA Author Manuscript

Year

Test system/animal model

Name of metabolite or derivative

Pharmacological effect

2011

U-46619 on human pulmonary
arteries

DHA monoacylglyceride induces 19, 20-epoxydocosapentaenoic acid

↑ RhoA and ↓ Ca2+
sensitivity

2011

Human bronchi and
ovalbumin-sensitized lung
tissue in guinea pig

DHA monoglyceride derivative CRBM-0244

↓ TNF-α-induced
inflammation, ↓ NF-κB
and ↓ COX-2

2011

Diabetic mice

14S,21R-dihydroxydocosa-4Z,7Z,10Z,12E,16Z,19Z-hexaenoic acid (14S,21R-diHDHA)

↑ wound healing and
angiogenesis

2009

C57BL/6J Diet-induced obesity

α-ethyl DHA ethyl ester

↓ Obesity,
↓Macrophage
infiltration, ↓adipocyte
hypertrophy and ↓ TGs,
NEFA and cholesterol

2006

Crystal structure ligandbinding domain and Cos cells

4-OH-DHA and 4-oxo-DHA out of 25 synthetic DHA derivatives

Potent anti-diabetic
comparable with
pioglitazone

2005

Cos-7 cells

5E-4-hydroxy-DHA and its keto derivatives out of 19 DHA derivatives

5E-4-hydroxy-DHA
fourfold stronger than
pioglitazone
4-keto derivative of
5E-4-hydroxy- antidiabetic activity

2005

Airway smooth muscle (guinea
pig)

DAG-containing DHA-1-stearoyl-2-docosahexaenoyl-sn-glycerol (SDHG)

DAGs ↑ ASM
contraction
SDHG ↑ tension
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